KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Payables (2016 - 2025)

Historic Payables for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $117.6 million.

  • Alnylam Pharmaceuticals' Payables rose 6607.73% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 6607.73%. This contributed to the annual value of $88.4 million for FY2024, which is 5925.18% up from last year.
  • Alnylam Pharmaceuticals' Payables amounted to $117.6 million in Q3 2025, which was up 6607.73% from $102.4 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Payables ranged from a high of $117.6 million in Q3 2025 and a low of $40.0 million during Q3 2021
  • Its 5-year average for Payables is $70.4 million, with a median of $70.8 million in 2024.
  • In the last 5 years, Alnylam Pharmaceuticals' Payables skyrocketed by 10317.32% in 2021 and then plummeted by 4340.22% in 2023.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Payables stood at $73.4 million in 2021, then soared by 33.6% to $98.1 million in 2022, then plummeted by 43.4% to $55.5 million in 2023, then soared by 59.25% to $88.4 million in 2024, then soared by 33.0% to $117.6 million in 2025.
  • Its Payables was $117.6 million in Q3 2025, compared to $102.4 million in Q2 2025 and $97.4 million in Q1 2025.